89bio, Inc. (ETNB)

NASDAQ: ETNB · IEX Real-Time Price · USD
4.74
+0.39 (8.97%)
At close: Aug 15, 2022 4:00 PM
4.85
+0.11 (2.32%)
After-hours: Aug 15, 2022 7:35 PM EDT
8.97%
Market Cap 185.21M
Revenue (ttm) n/a
Net Income (ttm) -105.24M
Shares Out 39.07M
EPS (ttm) -5.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 694,484
Open 4.38
Previous Close 4.35
Day's Range 4.36 - 4.80
52-Week Range 2.00 - 21.47
Beta 1.48
Analysts Buy
Price Target 24.10 (+408.4%)
Earnings Date Aug 10, 2022

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. [Read more...]

Industry Biotechnology
IPO Date Nov 11, 2019
Employees 41
Stock Exchange NASDAQ
Ticker Symbol ETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for ETNB stock is "Buy." The 12-month stock price forecast is 24.1, which is an increase of 408.44% from the latest price.

Price Target
$24.1
(408.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 -

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  SVB Leerink views these results as '...

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies...

89bio Posts Promising Pegozafermin Data For Severe Hypertriglyceridemia

89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).  Hypertriglyceridemia is characterized by high...

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies...

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies...

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertrigl...

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p

89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio Pulls Back With Market — But Could The Stock Soar 250%?

89bio, Inc (NASDAQ: ETNB) was plunging almost 10% lower on Friday in sympathy with the general market, which saw the S&P 500 plummeting over 2%. In May, a number of analysts weighed in on 89bio followin...

89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 -

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the tr...

89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH –

89bio Announces Appointment of E. Morrey Atkinson, Ph.D.

SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) ...

SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume

New sub-analysis presented at The Liver Meeting ® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients

89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN FRANCISCO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's The Liver Meeting 2021

Data from a new sub-analysis of the Phase 1b/2a study in NASH shows correlation between increased liver fat and spleen volume in patients with non-cirrhotic NASH Data from a new sub-analysis of the Phas...

89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH

- Study designed to build upon positive Phase 1b/2a data and provide an early opportunity to demonstrate BIO89-100's potential benefits on histology endpoints - - Study designed to build upon positive P...

89bio Reports First Quarter 2021 Financial Results and Provides Corporate Update

ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21 ENLIVEN Phase 2b trial in NASH expected to be initiated in 2Q21

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the tr...

89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 -

89bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -